Dynavax Technologies
Biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
Launch date
Employees
Market cap
AUD2.2b
Enterprise valuation
AUD1.5b (Public information from Sep 2024)
Share price
$11.21 DVAX
Berkeley California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 46.6m | 439m | 723m | 232m | 282m | 336m | 381m |
| % growth | 32 % | 844 % | 64 % | (68 %) | 21 % | 19 % | 13 % |
| EBITDA | (67.2m) | 142m | 298m | 21.0m | 1.3m | 28.4m | 41.6m |
| % EBITDA margin | (144 %) | 32 % | 41 % | 9 % | - | 8 % | 11 % |
| Profit | (75.2m) | 76.7m | 293m | (6.4m) | 25.7m | 51.0m | 67.8m |
| % profit margin | (162 %) | 17 % | 41 % | (3 %) | 9 % | 15 % | 18 % |
| EV / revenue | 10.5x | 3.4x | 1.9x | 5.7x | 3.2x | 2.4x | 1.8x |
| EV / EBITDA | -7.3x | 10.6x | 4.7x | 62.8x | 686.5x | 28.6x | 16.5x |
| R&D budget | 28.6m | 32.2m | 46.6m | 54.9m | - | - | - |
| R&D % of revenue | 61 % | 7 % | 6 % | 24 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$34.8m | Growth Equity VC | ||
| N/A | N/A | IPO | |
| N/A | $29.4m | Post IPO Equity | |
| N/A | $29.5m | Post IPO Equity | |
$30.0m | Post IPO Debt | ||
| N/A | $42.0m | Post IPO Equity | |
| N/A | $64.5m | Post IPO Equity | |
$40.0m | Debt | ||
* | N/A | $135m | Post IPO Equity |
* | N/A | $90.0m | Post IPO Equity |
| N/A | $80.8m | Post IPO Equity | |
| N/A | $175m | Post IPO Debt | |
* | N/A | $70.0m | Post IPO Equity |
| N/A | $80.5m | Post IPO Equity | |
$99.0m | Post IPO Debt | ||
* | $3.9m | Post IPO Equity | |
| Total Funding | AUD53.8m | ||
Related Content
Recent News about Dynavax Technologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.